Top-Journal Breakthrough (IF=81.2): Cloud-Clone AGE ELISA Kit Helps Uncover Protein Glycation Modification

CEB353Ge kit delivers critical molecular evidence for phase 3 clinical trial evaluating recombinant human serum albumin for cirrhotic ascites

HUSTON, TX, UNITED STATES, October 22, 2026 /EINPresswire.com/ -- Against the backdrop of rapid advances in biomedical science, landmark publications in high-impact academic journals define cutting-edge research directions worldwide. On 10 September 2026, a research team from the Liver Research Center at Beijing Friendship Hospital, Capital Medical University, published findings from a multicenter, randomized, double-blind, active-controlled phase 3 clinical trial in Signal Transduction and Targeted Therapy (Impact Factor = 81.2). Conducted across multiple clinical sites on patients with cirrhotic ascites, the study aimed to compare clinical performance between recombinant human serum albumin (rHSA) and plasma-derived human serum albumin (pHSA), and decipher glycation-driven molecular discrepancies between the two therapeutics. Researchers combined LC-MS molecular profiling with Cloud-Clone’s in-house-developed Advanced Glycation End-product (AGE) ELISA Kit (Catalog No. CEB353Ge), which provided robust quantitative datasets revealing key differences in molecular integrity of the two albumin preparations. This work establishes that albumin therapeutic assessment should consider not only protein quantity but also intrinsic molecular quality for future clinical applications.

Figure 1. Cover snapshot of the landmark phase-3 clinical-trial paper published in Signal Transduction and Targeted Therapy (10 September 2026, IF = 81.2). Cloud-Clone AGE ELISA Kit (CEB353Ge) supported molecular analysis within this study. Reference: Signal Transduct Target Ther. 2026 Sep 10;11:390. doi:10.1038/s41392-026-02951-7

1. Scientific Breakthrough Behind Top-Journal Publication: Reshaping Albumin Evaluation Criteria
Registered under trial ID NCT06553456, this phase 3 investigation enrolled 390 patients living with cirrhotic ascites. Designed with dual primary endpoints, the trial confirmed rHSA achieved equivalent serum-albumin elevation and non-inferior ascites-relief efficacy compared with conventional pHSA.
Notable insights emerged from exploratory endpoint analysis: glycated-albumin levels decreased by -12.24% within the rHSA cohort, whereas the pHSA group saw a +12.52% increase. This opposing trend attracted close scientific attention. Follow-up LC-MS characterization identified multiple non-enzymatic glycation sites on pHSA molecules. In contrast, rHSA produced via Pichia pastoris expression showed no detectable non-enzymatic glycation, demonstrating better-preserved, “younger” molecular integrity.
This finding highlights that future albumin therapeutic assessments should evaluate not only protein quantity, but also critical molecular quality. Precise quantification of AGE levels served as the core analytical cornerstone for this key conclusion.

2. Cloud-Clone CEB353Ge: Capturing Subtle Molecular-Level Biochemical Differences
High-sensitivity, high-specificity detection tools form the foundation of reliable experimental data for protein-glycation research. In this published study, researchers adopted Cloud-Clone in-house developed Advanced Glycation End-product (AGE) ELISA Kit (Catalog No. CEB353Ge).

Core Product Advantages
1.High Sensitivity & Specificity: Built on competitive-inhibition ELISA principle, CEB353Ge accurately quantifies AGE concentrations. It maintains minimal cross-reactivity and superior data reproducibility even within complex matrices such as finished albumin drug formulations.
2.Rigorous Quality Control: As a flagship Cloud-Clone product, this ELISA kit passes strict multi-step validation. Lot-to-lot stability enables standardized detection workflows for multicenter, large-sample clinical investigations.
3.Broad Application Scope: Beyond albumin-formula testing demonstrated in this trial, the kit supports research covering diabetic complications, ageing mechanisms, oxidative stress profiling, and quality assessment for diverse protein therapeutics.

Experimental Data Validates Real-World Performance
As presented in Figure 4(iii) of the original article, measurements generated with CEB353Ge revealed statistically significantly lower AGE concentrations for rHSA relative to pHSA (P < 0.05). These readouts directly confirm that recombinant albumin avoids glycation-associated molecular damage during manufacturing and retains superior molecular integrity. This supplies strong molecular-biology evidence supporting rHSA clinical safety and validates Cloud-Clone kit performance for detecting fine biochemical discrepancies.

Figure 2. AGE quantification results obtained using CEB353Ge ELISA kit. Comparison of AGE content between Pichia pastoris-expressed recombinant human serum albumin (rHSA) and plasma-derived human serum albumin (pHSA). pHSA exhibited significantly higher AGE levels than rHSA (P < 0.05). Samples: finished albumin pharmaceutical preparations. Assay method: competitive-inhibition ELISA. Catalog No.: CEB353Ge. Data extracted from Signal Transduction and Targeted Therapy, published 10 September 2026.
3. Critical Biological Role of AGE in Disease Research & Biopharmaceutical Development
Advanced Glycation End-products (AGEs) are stable covalent compounds formed via non-enzymatic reactions between reducing sugars and biomolecules including proteins, lipids or nucleic acids. Basal AGE concentrations remain low under physiological conditions, yet AGEs accumulate substantially during diabetes, chronic kidney disease, liver cirrhosis and biological ageing.

AGE as Disease Biomarker
Upon binding to the RAGE receptor, accumulated AGEs trigger NF-κB-mediated signalling cascades, driving inflammation and oxidative stress and inducing cellular injury. Reliable AGE measurement is therefore valuable for evaluating diabetic-complication risk, cardiovascular-disease progression and liver-disease severity.

Quality-Control Marker for Biopharmaceuticals
During recombinant-protein drug manufacturing (e.g. rHSA), host-cell metabolism, culture conditions and purification workflows may introduce unintended glycation modifications. Such alterations can change therapeutic half-life, immunogenic profile and biological activity. High-precision assays such as Cloud-Clone CEB353Ge are essential tools to monitor these critical quality attributes and safeguard drug safety and efficacy.

4. Why Choose Cloud-Clone: Globally Trusted Life-Science Reagent Supplier
Selecting knowledgeable, quality-focused reagent partners is vital to experimental success across life-science projects. Support for this high-impact IF = 81.2 publication represents another real-world validation of Cloud-Clone comprehensive technical strengths.
Validated by High-Impact Global Publications
This demanding clinical-sample research served as rigorous real-world testing for CEB353Ge performance. To date, Cloud-Clone reagents have been cited within more than 42 000 SCI-indexed publications, including over 350 high-profile studies featured in Nature, Science, Cell and other leading journals. Extensive literature references confirm Cloud-Clone reagents support researchers worldwide pursuing cutting-edge scientific discovery.
Full-chain In-house R&D & Manufacturing Capabilities
Cloud-Clone prioritizes original, in-house innovation. Large-scale investment has built dedicated R&D and production centres for protein, antibody and kit development, supplemented by three SPF-grade animal housing facilities and one SPF-grade experimental site (total floor area > 2 500 m²; SPF core area > 800 m²).
This infrastructure underpins complete technical workflows covering peptide synthesis, protein expression & purification, antibody generation and final kit assembly. All core raw materials are 100 % produced internally with full traceability. Independent in-house production secures stable supply capacity, enables strict batch-level raw-material oversight and consistently maintains high product quality.
Global Footprint & Internationally-Recognized Compliance Certifications
Cloud-Clone operates as an international enterprise with strict compliance frameworks. Products and services reach researchers across more than 50 countries, with long-term collaborative partnerships with globally recognized organizations. Quality-system accreditations include ISO 9001, ISO 13485, ISO 14001, SPF and CMA. Cloud-Clone ELISA kits have also received the international CiteAB award for outstanding product performance. These credentials assure end-users of products and services aligned with global quality benchmarks.
Fast Response, Customization & Comprehensive Technical Support
Cloud-Clone prioritizes researcher requirements. The support team guarantees response within 24 hours and completed return-and-exchange handling within 72 hours. Beyond standard off-the-shelf reagents, custom-development services are available for project-specific experimental needs. Expert technical staff deliver end-to-end assistance spanning product consultation, application guidance, experimental design and data interpretation.

5. Cloud-Clone Total Solution Portfolio for AGE-focused Research
To meet diverse experimental requirements for AGE-related studies, Cloud-Clone provides the top-journal-validated CEB353Ge competitive-ELISA kit alongside a complete AGE-targeted product portfolio, encompassing antibodies, native / active proteins and multiplex detection platforms for streamlined one-stop research solutions.
Note: All products listed below are for research-use-only; not intended for clinical diagnostic applications.

Figure 3 List of Cloud-Clone AGE-related reagent products.

Published 10 September 2026, this Capital Medical University clinical study expands future clinical opportunities for recombinant human serum albumin and raises higher standards for molecular-quality monitoring of protein therapeutics. Cloud-Clone CEB353Ge AGE ELISA kit delivered critical analytical performance within this landmark investigation.
Moving forward, Cloud-Clone will keep pursuing precision, efficiency and innovation, delivering premium reagents and services for global investigators and facilitating more high-calibre scientific outputs. Researchers conducting AGE-related studies or protein-drug quality-control projects are welcome to contact Cloud-Clone for detailed product consultation.
Disclaimer: Literature figures and dataset referenced are reproduced from Signal Transduction and Targeted Therapy (2026) 11:390. All product specifications are sourced from official Cloud-Clone Corp. documentation. Products are for research-use-only and are not for human clinical diagnosis.

About Cloud-Clone Corp.
Cloud-Clone Corp. is dedicated to the development and production of high-quality immunoassay reagents and detection solutions. With a focus on antibody engineering, multiplex assay development, and cross-platform compatibility, the company provides research tools designed to support precision medicine and advanced biomedical investigation globally. Our core products and services include the research and development of proteins, antibodies, ELISA kits, primary cells, and multiplex cytokine assay kits, as well as professional CRO services to fully meet the diverse needs of biomedical research and related fields.
For more information about Cloud-Clone Corp, visit www.cloud-clone.com.

CLOUD-CLONE CORP.(CCC)
Tel: 001-832-538-0970, 0086-27-8425-9552
Email: [email protected], [email protected]

Visit us on social media:
LinkedIn: https://www.linkedin.com/company/cloud-clone-corp/
Instagram: https://www.instagram.com/cloudclonecorp2023/
TickTok: https://www.tiktok.com/@cloudclonecorp2026

SuKi Duan
CLOUD-CLONE CORP.WUHAN
email us here
Visit us on social media:
LinkedIn
Instagram
TikTok
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

Top-Journal Breakthrough (IF=81.2): Cloud-Clone AGE ELISA Kit Helps Uncover Protein Glycation Modification

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.